After this session electrophysiologists will be able to identify the causes of sub-optimal outcomes in atrial ablation, describe the convergent procedure and appropriate patients, and outline the electrophysiologist’s role.
Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
assess the interrelationships linking diabetes, HF and CVD;
interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
To highlight the continued high unmet need for strategies to prevent stroke or death for patients experiencing acute stroke or TIA
To outline the guidelines on the use of dual antiplatelet therapy for patients presenting with acute stroke or TIA
To examine recent evidence from clinical trials on novel strategies for improving outcomes for patients presenting with acute stroke or TIA and how these data and insights can be applied in clinical practice